Gilead CEO on remdesivir: manufacturing, pricing for coronavirus drug - Business Insider

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 50 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 23%
  • Publisher: 51%

ประเทศไทย ข่าว ข่าว

ประเทศไทย ข่าวล่าสุด,ประเทศไทย หัวข้อข่าว

Gilead plans to spend up to $1 billion to ramp up manufacturing of its coronavirus treatment, but execs dodged Wall Street's questions about turning a profit

Join BI PrimeThe California biotech giant Gilead Sciences is planning to spend up to $1 billion to ramp up production of itsThe manufacturing ambitions come before the antiviral drug is approved by any health regulators for use in COVID-19, the disease caused by the coronavirus.

The ultimate size of the investment will depend on how the drug's data and the pandemic evolve, said Andrew Dickinson, Gilead's chief financial officer. Through the end of March, Gilead had spent about $50 million on remdesivir, without knowing whether or not it worked. Looking beyond the immediate term, Gilead executives declined to say how they'll set a price for the pill, which is now the frontrunner to be the first effective coronavirus treatment. Hospitalized patients who got remdesivir recovered 31% faster than a group taking placebo, the US National Institutes of Health found in a clinical trial.

SVB Leerink biotech analyst Geoff Porges, for instance, referenced the profit margins Gilead has made selling medicines for other infectious diseases like HIV and Hepatitis C."I don't think there is a precedent for this," O'Day replied, saying a market for a COVID-19 treatment will be unique and different from these other diseases.

 

ขอบคุณสำหรับความคิดเห็นของคุณ ความคิดเห็นของคุณจะถูกเผยแพร่หลังจากได้รับการตรวจสอบแล้ว

Big pharma sux.

เราได้สรุปข่าวนี้มาให้อ่านอย่างรวดเร็ว หากสนใจข่าว สามารถอ่านฉบับเต็มได้ที่นี่ อ่านเพิ่มเติม:

 /  🏆 729. in TH

ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว

Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้

Coronavirus treatment: Gilead says positive data on remdesivir coming - Business InsiderOne of the most promising coronavirus treatment candidates succeeded in a late-stage trial in COVID-19 patients, Gilead said Wednesday.
แหล่ง: BusinessInsider - 🏆 729. / 51 อ่านเพิ่มเติม »

Tesla's Elon Musk doesn't behave like any other CEO in the business - Business InsiderEveryone has to accept that Tesla is worth $150 billion precisely because Elon Musk doesn't behave like any other CEO in the business High on something? Doesn’t mean he gets to have an effect on government decisions Musk has his heart & soul invested in his businesses. Look at it from that point of view. 👀
แหล่ง: BusinessInsider - 🏆 729. / 51 อ่านเพิ่มเติม »

Tesla's Elon Musk doesn't behave like any other CEO in the business - Business InsiderEveryone has to accept that Tesla is worth $150 billion precisely because Elon Musk doesn't behave like any other CEO in the business Get off his 🥜 Don’t take drugs kiddies! Cause he post memes no he’s just like the rest
แหล่ง: BusinessInsider - 🏆 729. / 51 อ่านเพิ่มเติม »

Billionaire Bill Ackman has 'enormous respect' for Tesla CEO Elon Musk - Business InsiderBillionaire investor Bill Ackman has 'enormous respect' for Tesla chief Elon Musk, but isn't a fan of his tweets What more is there to Elon than his tweets?
แหล่ง: BusinessInsider - 🏆 729. / 51 อ่านเพิ่มเติม »

Barclays' CEO says crowded offices could be 'a thing of the past' - Business InsiderAcross Wall Street, banks are rethinking how to safely return workers to offices which could look radically different in a post-pandemic world.
แหล่ง: BusinessInsider - 🏆 729. / 51 อ่านเพิ่มเติม »

Man Group CEO Luke Ellis says many employees will be working from home - Business InsiderMany financial services firms have been pleasantly surprised with how effective work-from-home policies have been during the coronavirus pandemic. The new Normal.. so long NYC BIGRENT
แหล่ง: BusinessInsider - 🏆 729. / 51 อ่านเพิ่มเติม »